FY2026 Earnings Estimate for Albemarle Issued By Scotiabank

Albemarle Corporation (NYSE:ALB) – Equities research analysts at Scotiabank issued their FY2026 earnings per share (EPS) estimates for shares of Albemarle in a research report issued on Monday, November 2nd. Scotiabank analyst B. Isaacson forecasts that the specialty chemicals company will post earnings of $11.64 per share for the year. Scotiabank currently has a “Sector Outperform” rating and a $190.00 target price on the stock. The consensus estimate for Albemarle’s current full-year earnings is $11.15 per share. Scotiabank also issued estimates for Albemarle’s FY2027 earnings at $14.15 EPS.

Albemarle (NYSE:ALB) last issued its earnings results on Wednesday, November 4th. The specialty chemicals company reported $2.58 EPS for the quarter, topping analysts’ consensus estimates of $2.53 by $0.05. The firm had revenue of $1.55 billion for the quarter, compared to the consensus estimate of $1.52 billion. Albemarle had a return on equity of 15.23% and a net margin of 10.40%. The company’s revenue was up 18.8% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($0.19) earnings per share.

Other equities research analysts have also recently issued research reports about the stock. Citigroup lowered their target price on shares of Albemarle from $175.00 to $125.00 and set a “buy” rating on the stock in a research note on Thursday, October 22nd. Argus cut their price objective on Albemarle from $230.00 to $135.00 and set a “buy” rating for the company in a research report on Wednesday, October 7th. Barclays initiated coverage on shares of Albemarle in a research report on Monday, October 12th. They issued an “equal weight” rating and a $109.00 target price on the stock. UBS Group decreased their target price on shares of Albemarle from $175.00 to $150.00 and set a “buy” rating on the stock in a research report on Monday, October 5th. Finally, JPMorgan Chase & Co. lowered their target price on shares of Albemarle from $160.00 to $140.00 and set a “neutral” rating for the company in a research note on Tuesday, August 25th. Fifteen investment analysts have rated the stock with a Buy rating, seven have issued a Hold rating and three have given a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $179.41.

Albemarle Price Performance

Shares of NYSE ALB opened at $98.25 on Friday. The firm’s 50 day simple moving average is $108.33 and its 200-day simple moving average is $148.24. The company has a debt-to-equity ratio of 0.22, a current ratio of 2.09 and a quick ratio of 1.35. Albemarle has a 12 month low of $89.77 and a 12 month high of $221.00. The stock has a market capitalization of $11.59 billion, a price-to-earnings ratio of 23.73, a PEG ratio of 0.57 and a beta of 1.34.

Institutional Trading of Albemarle

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Sigma Planning Corp raised its position in shares of Albemarle by 2.3% in the first quarter. Sigma Planning Corp now owns 2,952 shares of the specialty chemicals company’s stock valued at $530,000 after buying an additional 66 shares during the last quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS boosted its position in Albemarle by 0.3% during the first quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 27,452 shares of the specialty chemicals company’s stock worth $4,928,000 after acquiring an additional 75 shares during the last quarter. Allspring Global Investments Holdings LLC boosted its position in Albemarle by 0.6% during the first quarter. Allspring Global Investments Holdings LLC now owns 11,664 shares of the specialty chemicals company’s stock worth $2,082,000 after acquiring an additional 75 shares during the last quarter. Cadence Wealth Management LLC boosted its position in Albemarle by 1.8% during the first quarter. Cadence Wealth Management LLC now owns 4,982 shares of the specialty chemicals company’s stock worth $894,000 after acquiring an additional 87 shares during the last quarter. Finally, Parkside Financial Bank & Trust grew its stake in Albemarle by 7.0% in the 2nd quarter. Parkside Financial Bank & Trust now owns 1,584 shares of the specialty chemicals company’s stock worth $214,000 after acquiring an additional 103 shares during the period. 92.87% of the stock is owned by hedge funds and other institutional investors.

Albemarle Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Monday, January 4th. Investors of record on Friday, December 18th will be given a $0.41 dividend. The ex-dividend date of this dividend is Friday, December 18th. This represents a $1.64 dividend on an annualized basis and a dividend yield of 1.7%. Albemarle’s dividend payout ratio is 39.61%.

Trending Headlines about Albemarle

Here are the key news stories impacting Albemarle this week:

• Positive Sentiment: Albemarle reported Q3 adjusted earnings of $2.58 per share, ahead of analyst estimates, and revenue of $1.55 billion, also above expectations and up 18.8% year over year. Higher lithium prices drove a sharp profit increase and stronger cash flow, supporting the positive investor case. Read More. · Read More.

About Albemarle

Albemarle Corporation (NYSE: ALB) is a global specialty chemicals company headquartered in Charlotte, North Carolina. The company develops, manufactures, and markets engineered chemicals used in energy storage, transportation, refining, pharmaceuticals, agriculture, consumer products, and other industrial applications.

Albemarle is one of the world’s major producers of lithium and supplies lithium compounds, including lithium carbonate and lithium hydroxide, for use in rechargeable batteries for electric vehicles, portable electronics, and grid energy-storage systems.